H.C. Wainwright & Co. Announces Two New Hires

H.C. Wainwright & Co. has made two hires to its life sciences equity research group. Dr. Reni J. Benjamin and Caroline Y. Stewart have both been named managing directors and senior biotechnology analysts. Prior to joining HCW, Dr. Benjamin worked at Burrill & Company where he was a managing director and senior analyst while Stewart served as senior manager of US finance at Sanofi. Headquartered in New York City, HCW is an investment bank.


NEW YORK–(BUSINESS WIRE)–H.C. Wainwright & Co., LLC (“HCW”) today announced two significant additions to its Life Sciences Equity Research group to further strengthen its position in the biotechnology and life sciences sectors.
Reni J. Benjamin, Ph.D. joins HCW as a Managing Director and Senior Biotechnology Analyst focusing on the oncology and stem cell sectors. Dr. Benjamin joins HCW from Burrill & Company where he was a Managing Director and Senior Analyst. Prior to Burrill, Dr. Benjamin worked for approximately 10 years as a Senior Analyst at Rodman & Renshaw, LLC where he played an integral role in building the premier small- and mid-cap biotechnology franchise on Wall Street. Dr. Benjamin has previously been ranked among the top analysts for recommendation performance and earnings accuracy by StarMine, been cited in a variety of sources including the Wall Street Journal, Business Week, Financial Times and Smart Money, and has made regular appearances on Bloomberg television, radio and CNBC.
Caroline Y. Stewart joins HCW as a Managing Director and Senior Biotechnology Analyst focusing on the oncology and women’s health sectors. Ms. Stewart returns to sell-side equity research after approximately 4 years in industry, having most recently been Senior Manager, US Finance at Sanofi and, prior to that, as a Director of Investor Relations at Merck. She previously had held the position of Senior Biotechnology Analyst at Piper Jaffray and was a research associate at Morgan Joseph, Salomon Smith Barney and Deutsche Bank.
Dr. Benjamin and Ms. Stewart join Andrew Fein, who was hired by HCW in June, to comprise the senior biotechnology research team at HCW. Prior to joining HCW, Mr. Fein held a number of Senior Analyst positions at several firms including Jefferies, Piper Jaffray, Collins Stewart, Leerink Swann and JP Morgan.
Commented Mark Viklund, HCW’s Chief Executive Officer, “The addition of Ren and Caroline further underscore HCW’s commitment to the biotechnology sector. Ren’s, Andrew’s and Caroline’s deep domain expertise will enable HCW to assist clients in uncovering unparalleled investment opportunities in the small- and mid-cap biotechnology sectors.”
About H.C. Wainwright & Co., LLC
H.C. Wainwright & Co., LLC is an investment bank dedicated to providing corporate finance, strategic advisory and related services to public and private growth companies across multiple sectors and regions. The H.C. Wainwright team has been the leader in the PIPE (private investment in public equity) and RD (registered direct offering) transaction markets. H.C. Wainwright was established in 1868 and is headquartered in New York City.